Loading clinical trials...

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis | Clinical Trials | Clareo Health

RECRUITING

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

A Non-interventional, Multi-centric, Single Country Observational Study to Assess the Safety and Effectiveness of Guselkumab After Ustekinumab (Originator or Biosimilar) in Moderate to Severe Psoriasis Patients in Clinical Routine

NCT07449234•Janssen-Cilag Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the effectiveness and safety of guselkumab following a switch from ustekinumab or an ustekinumab biosimilar in participants with moderate to severe psoriasis, a chronic inflammatory skin disease characterized by erythematous, scaly plaques that may be associated with pain and pruritus, in routine clinical practice.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Must have a confirmed diagnosis of moderate-to-severe plaque psoriasis requiring systemic treatment
•Participants who are currently treated with Ustekinumab (either the originator or its biosimilar) and who are medically indicated to switch to Guselkumab
•Participants who, based on the Investigator's decision, should initiate treatment with Guselkumab
•Participants must understand and be willing and able to answer patient-reported outcomes (PROs)
•Must sign an informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements

Exclusion Criteria

•Contraindication or hypersensitivity to Guselkumab or any ingredient in the injection solution/liquid
•Pregnancy or breastfeeding
•Currently enrolled in an interventional study
•Currently enrolled in an observational study sponsored or managed by a Janssen company

Locations (1)

LKH-Univ. Klinikum Graz

Graz, Austria

Key Dates

Start Date

February 9, 2026

Primary Completion Date

March 15, 2027

Completion Date

September 1, 2027

Last Updated

March 13, 2026

Enrollment

200

ESTIMATED participants

Conditions

Psoriasis

Contacts

Study Contact

CONTACT

844-434-4210 Participate-In-This-Study1@its.jnj.com

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967

Plaque Psoriasis

View study

RECRUITINGPHASE3

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802

Plaque Psoriasis

View study

RECRUITINGPHASE2

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

NCT07449702

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 13, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

Inclusion Criteria

Exclusion Criteria

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

Real-Life Evaluation of Guselkumab Dosing Interval Adjustments

SEquential Treatment of PSoriasis With Biologics